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Background: This study was conducted to assess whether patient-reported outcomes (PROs) differ by the
underlying diagnosis (rheumatoid arthritis (RA)/inflammatory arthritis, osteoarthritis (OA), avascular necrosis of bone
(AVN), other) in patients undergoing primary total hip arthroplasty (THA).
Methods: We used prospectively collected data to assess the association of diagnosis with index hip function and
pain. Moderate-severe activity limitation and moderate-severe pain were assessed at two- and five-year follow-up
after primary THA using multivariable-adjusted logistic regression analyses. Odds ratios (OR) and 95% confidence
intervals (CI) were calculated.
Results: There were 5,707 primary THAs at two-years and 3,289 at five-years, 51% were women and the mean age
was 65 years. The underlying diagnosis was RA in 3%, OA in 87%, AVN in 7% and other in 3%. In multivariable-
adjusted analyses, compared to RA, diagnoses of OA and AVN were significantly associated with lower odds of
moderate-severe activities of daily living limitations with an OR (95% CI) of 0.5 (0.3 to 0.8) (P = 0.01) and 0.4 (0.2 to
0.8) (P = 0.01), respectively, at two-years, but not at five-years, 0.7 (0.4 to 1.4) (P = 0.36) and 0.9 (0.4 to 1.8) (P = 0.78),
respectively. At two-years, neither OA nor AVN were significantly associated with higher odds of moderate-severe
pain (1.6 (0.6 to 4.5) (P = 0.40) and 2.8 (0.9 to 8.5) (P =0 0.06)), respectively. At five-years, AVN was associated with
higher odds of moderate-severe pain with OR 4.1 (1.2 to 14.1) (P = 0.02), but not OA, 2.1 (0.7 to 6.5) (P = 0.22).
Conclusions: We found that patients with OA and AVN had better functional outcomes and those with AVN worse
pain outcomes after primary THA, compared to patients with RA/inflammatory arthritis. Insights into mediators of
these relationships are needed to better understand these associations.
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Total hip arthroplasty (THA) has been termed the oper-
ation of the century [1]. In patients with end-stage
refractory hip arthritis or other hip problems, THA pro-
vides significant improvement in pain, function and
quality of life [2,3], which are the main reasons why pa-
tients undergo this procedure. A population-based study
showed that the volume of THA is increasing rapidly
with a significant increase in the last 10 years [4]; this in-
crease is also reported in other landmark studies [5-7].
Previous studies have focused on surgical and implant
factors affecting the risk of revision after THA. Although
several studies have examined the factors associated with
patient-reported outcomes (PROs) after THA, many
fewer studies have examined the effect of underlying
diagnosis on pain and functional outcomes post-THA.
Most elective THAs are done for osteoarthritis (OA) or
rheumatoid arthritis (RA) and a small proportion for
avascular necrosis of bone (AVN; <5%).
Do patients with OA have better PROs after primary
THA compared to RA? The published literature is
sparse and the answer unclear. In the largest of pub-
lished studies, 381 patients were studied with two-year
follow-up in 331 and five-year follow-up in 89 patients,
pain and function (walking scores) at two years post-
THA did not differ by the underlying diagnosis [8]. In
other studies, compared to OA, RA was associated with
worse functional outcomes at one year after THA [9],
less pain and functional improvements at 2.5 years post-
arthroplasty in a study that combined patients with
THA and total knee arthroplasty [10] and worse func-
tional outcome at 10 years after THA (compared to his-
torical controls) [11]. However, none of the studies with
positive findings adjusted for important covariates and
confounders, implying that they may potentially be false
positive. Other major limitations of previous studies are
that the follow-up was short and most had very few pa-
tients with RA. Therefore, it is unclear whether the
underlying diagnosis is independently associated with
outcomes after primary THA. Our objective was to as-
sess the association of underlying diagnosis with pain
and functional outcomes using a large total joint registry
sample and adjusting for important covariates/con-
founders. We hypothesized that patients with OA as the
underlying diagnosis will have better, and AVN worse,
pain and functional outcomes after primary THA com-
pared to patients with RA after adjusting for important
covariates and confounders of pain and functional
outcomes.
Methods
The methods and results are described as recommended
in the Strengthening of Reporting in Observational stud-
ies in Epidemiology (STROBE) statement [12].Setting, participants and data sources
For this study, we used the Mayo Total Joint Registry
that prospectively collects data on all joint replacements
performed at the Mayo Clinic, Rochester, MN, USA.
Data in the registry include patient demographics, op-
erative diagnosis, surgery and implant details, dates of
evaluation, reoperations and complications, current ra-
diographs and pain and functional assessments [13,14].
All patients who undergo THA at the Mayo Clinic are
requested to complete a validated Mayo Hip questionnaire
preoperatively and at two- and five-year follow-ups.
The Mayo hip questionnaire has face, content and con-
struct validity and test-retest reliability [15-17]. The
pain and function questions are similar to those in the
validated Harris Hip Score [18], the most widely used
questionnaire in THA patients. The Mayo Hip question-
naires are mailed to the patients, administered during the
clinic visit or by telephone by experienced, dedicated joint
registry staff. Questionnaire data have been captured elec-
tronically starting in 1993. Patients were included in this
study if they had undergone a primary THA from 1993 to
2005 and had responded to the Mayo hip survey at the
two-year or five-year follow-up. Patients of all ages were
included. The Institutional Review Board (IRB) at the
Mayo Clinic, Rochester, MN, USA approved the study.
Since it was a database study, the IRB waived the need
for an informed consent.
Predictors of interest and covariates
The operative diagnosis was the main variable of inter-
est, categorized as osteoarthritis (OA), rheumatoid or in-
flammatory arthritis (RA), avascular necrosis of bone
(AVN) and other. This was based on preoperative diag-
nosis (based on history, clinical examination, medica-
tions and the results of radiographic and other studies)
as well as operative findings. We adjusted for covariates
that included known and suspected correlates of pain
and function after THA. Covariates were demographics
(age, gender), body mass index (BMI), American Society
of Anesthesiologist (ASA) class, distance from the med-
ical center and implant fixation (uncemented, hybrid/
cemented) obtained from the Total Joint Registry and
linked databases. Anxiety, depression and medical co-
morbidity using the validated Deyo-Charlson index [19]
were based on the presence of International Classifica-
tion of Diseases-ninth revision, common modification
(ICD-9-CM) codes in the Mayo Clinic electronic data-
bases, derived from administrative and clinical records.
Distance from the medical center was included, since
Mayo Clinic provides THA to local residents as well as re-
ferred patients traveling from far, who may have different
disease severity and expectations, and both can impact
pain and function outcomes [20-22]. In addition, we
adjusted all functional outcome models for preoperative
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seven activities of daily living (ADLs) and the pain models
for preoperative pain severity, respectively.
Outcomes of interest
Study outcomes were PROs of moderate-severe ADL limi-
tation and moderate-severe pain obtained from self-
reported validated Mayo hip questionnaires at two years
or five years (reference, no/mild categories) after THA.
We defined these composite outcomes a priori as undesir-
able outcomes of THA as in previous studies [23,24], since
THA is done primarily to relieve pain and improve func-
tion. Similar pain and ADL questions were also adminis-
tered preoperatively; details are in Additional file 1:
Table S1. For patients with multiple procedures, the lat-
est observation for the index hip arthroplasty that was
available prior to an additional procedure (and qualified
for the two- or the five-year time point) was used as a
conservative approach.
Patients self reported limitations in seven key ADLs
that specifically assessed index hip function, including
walking, climbing stairs, putting on shoes/socks, picking
up objects from the floor, sitting in a chair, getting in/
out of the car and rising from a chair to a standing pos-
ition. For four ADLs (walking, climbing stairs, sitting
and rising from a chair), limitations were categorized
into ‘no’, ‘mild’, ‘moderate’ or ‘severe’ limitation. The
remaining three ADLs (putting on shoes/socks, picking
up objects from the floor and getting in/out of the car),
that did not have a response corresponding to the ‘mild’
category, were categorized into ‘no’, ‘moderate’ or ‘severe’
limitation, as previously [23]. The presence of three or
more ADLs with moderate or severe limitation was classi-
fied as overall moderate to severe ADL limitation (refer-
ence, all other categories), as previously described [19].
Postoperative index hip pain was assessed with a single
question on the hip questionnaire, namely ‘Do you have
pain in the hip in which the joint was replaced? no pain,
slight, moderate, severe.’ This validated question [15-17]
is similar to the pain question in the Harris Hip Score, a
commonly used THA outcome instrument that is valid,
reliable and sensitive to change [25-27].
Bias and sample size
We tried to minimize confounding bias by including
several covariates previously known or suspected to be
associated with pain and ADL limitation after THA
including the preoperative status, but recognize that re-
sidual confounding is a limitation of cohort study design.
We accounted for correlation of observations (due to bi-
lateral THA in patients, simultaneously or sequentially)
using appropriate statistical methods. We anticipated
non-response to be higher at five than at two years, and
acknowledge this as a study limitation limiting thegeneralizability of results. We included a large enough
sample to study pain and ADL limitation without having
too long of a study period (to avoid significant secular
trends in implants and procedure) and, therefore, chose
all eligible patients from 1993 to 2005. No formal sample
size calculations were done.
Statistical analyses
We used univariate and multivariable-adjusted logistic
regression models to assess the association between the
operative diagnosis and moderate-severe ADL limitation
and moderate-severe pain two and five years after pri-
mary THA. The multivariable models included age, gen-
der, BMI, ASA class, distance from the medical center,
implant fixation, Deyo-Charlson index, anxiety and de-
pression as well as respective preoperative variable/s –
preoperative pain for pain outcome and preoperative
limitation in seven ADLs for ADL limitation outcome.
Individual ADL limitations were only examined as ex-
ploratory analyses, to avoid multiple comparisons and
results are presented in Additional file 1. Odds ratios
(OR), 95% confidence intervals (CI), and P-values are
reported. Subgroup analyses were done for patients
younger and older than 65 years to assess the association
of diagnosis with pain and ADL outcomes, since patients
with AVN or RA are expected to be younger than those
with OA. We performed sensitivity analyses by
restricting the study sample to surgery from 1998 to
2005, to examine whether change in RA management in
the recent years impacted the noted associations in the
main analyses.
All regression analyses used a generalized estimating
equations (GEE) approach to adjust the standard errors
for the correlation between observations on the same sub-
ject due to both hips having been replaced. Responder and
non-responder characteristics were compared using logis-
tic regression analyses, which were pre-specified to in-
clude demographics, comorbidity, implant-related factors
and underlying diagnosis. We decided a priori not to
impute any missing data and to treat them as missing.
A P-value <0.05 was considered significant. Analyses
were done using SPSS, version 21 (Chicago, IL, USA).
IRB approval
The Mayo Clinic Institutional Review Board approved
this study and all investigations were conducted in con-
formity with ethical principles of research.
Results
Clinical and demographic characteristics are shown in
Additional file 1: Table S2. A total of 5,707 patients pro-
vided data for the two-year and 3,289 for the five-year
follow-up. For the two-year cohort, the mean age was 65
years, 51% were women, and 30% were ≤60 years. BMI
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class III/IV in 38%. The underlying diagnosis was OA in
87%, RA or inflammatory arthritis in 3% and AVN in 7%
(3%, other). Mean Deyo-Charlson score was 1 and depres-
sion and anxiety were present in 7% and 5%, respectively.
Characteristics were similar in the five-year cohort and
also similar to patients who responded to the preoperative
questionnaire [see Additional file 1: Table S2]. Baseline
characteristics of the patients at 2-year follow-up
according to their diagnosis are shown in Table 1.Table 1 Characteristics of patients with OA, RA, AVN and
other diagnoses (2-year cohort)
Diagnosis (%) or mean (SD)
RA OA AVN Other
(n=162) (n = 5,339) (n = 456) (n=211)
Agea 56 (17) 65 (13) 57 (17) 50 (15)
% women 65% 51% 49% 66%
BMI (kg/m2) 26 (5) 29 (6) 27 (6) 27 (6)
Age groupsa
≤60 yrs 45% 29% 52% 72%
>60 to 70 yrs 31% 31% 23% 19%
>70 to 80 yrs 23% 31% 19% 9%
>80 yrs 1% 9% 6% 1%
BMI (kg/m2)
<25 46% 23% 32% 40%
25 to 29.9 33% 39% 41% 31%
30 to 34.9 13% 25% 17% 22%
35 to 39.9 6% 9% 5% 5%
≥40 2% 5% 4% 2%
ASA scorea
Class I 5% 5% 8% 15%
Class II 46% 57% 49% 55%
Class III 49% 36% 42% 28%
Class IV 0% 1% 1% 1%
Implant Fixationa
Cemented 8% 12% 12% 8%
Hybrid 66% 52% 48% 54%
Uncemented 26% 36% 41% 38%
Deyo-Charlson Index 1 (1) 1 (2) 1 (2) 1 (2)
Depression 7% 7% 8% 4%
Anxiety 3% 4% 8% 2%
Distance Category
0 to 100 miles 43% 48% 38% 36%
>100 to 500 miles 47% 41% 49% 50%
>500 miles or non-US 11% 11% 13% 14%
Numbers rounded to the nearest digit. ap<0.05 ASA, American Society of
Anesthesiologists; AVN, avascular necrosis of bone; BMI, body mass index; OA,
osteoarthritis; RA, rheumatoid arthritis; SD, standard deviation.Compared to patients with RA/inflammatory arthritis,
those with OA were less likely to be women and more
likely to be older or obese and those with AVN less likely
to be women and more likely to be obese. There was little
variation in the prevalence of moderate-severe pain (91%
to 95%) and moderate-severe activity limitation (70% to
80%) by diagnosis preoperatively [see Additional file 1:
Table S3]. The survey response rates were 62% (5,707/
9,154) at the two-year and 53% (3,289/6,243) at the five-
year follow-up.
Responder characteristics
Responders to the two-year post-primary THA survey
were more likely to be older (age 61 to 70, 71 to 80 and
>80 with ORs = 1.4, 1.3 and 1.3, respectively, compared
to ≤60 years) and less likely to have BMI ≥40 (OR, 0.7),
ASA class III-IV (OR, 0.9) or live further from the med-
ical center (distance >100 to 500, OR, 0.9; and >500
miles with OR, 0.7) (Table 2). At five years, responders
were more likely to be older (age 61 to 70 with OR, 1.4;
71 to 80 with OR, 1.4), have a BMI = 25 to 29.9 (OR,
1.2), and less likely to live further from the medical cen-
ter (distance >100 to 500 with OR = 0.9 and >500 miles
with OR = 0.6).
Univariate association of diagnosis with pain and overall
activity limitation
In unadjusted analyses, we noted that compared to RA/
inflammatory arthritis, the odds of overall moderate-
severe ADL limitation at two years were significantly
lower in OA and AVN patients (Table 3). On the other
hand, compared to RA/ inflammatory arthritis, the odds
of moderate-severe pain at two years were significantly
higher in patients with OA (Table 3). Similar findings
were noted at 5-years, except that moderate-severe pain
associations at 5-years were only borderline significant
(P = 0.07).
Multivariable-adjusted association of diagnosis with
overall activity limitation and pain
In adjusted analyses, compared to patients with RA/
inflammatory arthritis, those with OA and AVN had sig-
nificantly lower odds of overall moderate-severe ADL
limitation at two years (Table 4). No differences by diag-
nosis were noted in moderate-severe pain at two years.
Compared to patients with RA, patients with AVN and
other diagnosis had significantly higher odds of moderate-
severe pain at five years, but no significant differences in
moderate-severe ADL limitation at five years (Table 4).
Sensitivity analyses performed by restricting the analyses
to the time period of surgery to 1998 to 2005 revealed
minimal change in ORs and no change in significance for
association of OA or AVN with moderate-severe activity
limitations at two years, with ORs of 0.4 (95% CI, 0.2
Table 2 Characteristics of responders to Mayo Hip Questionnaire (pain and functional limitation) for primary THA
Two years Five years
Variable Events for responders Odds ratio
(95% CI)




Female 1976/4736 (41.7%) 1244/3281 (37.9%)
Male 1847/4418 (41.8%) 1.0 (0.9 to 1.1) 0.94 1130/2962 (38.1%) 1.0 (0.9 to 1.1) 0.85
Age Category
< 60 1176/2988 (39.4%) 737/2075 (35.5%)
61 to 70 1204/2676 (45%) 1.3 (1.1 to 1.4) <0.01 791/1893 (41.8%) 1.3 (1.1 to 1.5) <.01
71 to 80 1121/2706 (41.4%) 1.1 (1.0 to 1.2) 0.12 706/1841 (38.3%) 1.1 (1.0 to 1.3) 0.08
>80 322/784 (41.1%) 1.1 (0.9 to 1.3) 0.40 140/434 (32.3%) 0.9 (0.7 to 1.1) 0.20
BMI Category
<25 935/2221 (42.1%) 571/1570 (36.4%)
25 to 29.9 1493/3477 (42.9%) 1.0 (0.9 to 1.2) 0.54 954/2393 (39.9%) 1.2 (1.0 to 1.3) 0.03
30 to 34.9 907/2209 (41.1%) 1.0 (0.8 to 1.1) 0.49 548/1479 (37.1%) 1.0 (0.9 to 1.2) 0.70
35 to 39.9 309/786 (39.3%) 0.9 (0.8 to 1.1) 0.19 187/515 (36.3%) 1.0 (0.8 to 1.2) 0.98
>40 161/419 (38.4%) 0.9 (0.7 to 1.1) 0.17 102/259 (39.4%) 1.1 (0.9 to 1.5) 0.38
ASA Score
1 to 2 2410/5608 (43%) 1539/3950 (39%)
3 to 4 1396/3509 (39.8%) 0.9 (0.8 to 1.0) <0.01 823/2261 (36.4%) 0.9 (0.8 to 1.0) 0.05
Charlson Index (5 point increase) N/A 0.8 (0.7 to 0.9) N/A 0.9 (0.7 to 1.0) 0.05
Distance Category
0 to 100 miles 1785/4145 (43.1%) 1093/2743 (39.8%)
>100 to 500 miles 1531/3695 (41.4%) 0.9 (0.9 to 1.0) 0.16 935/2520 (37.1%) 0.9 (0.8 to 1.0) 0.05
>500 miles or non-US 381/988 (38.6%) 0.8 (0.7 to 1.0) 0.01 220/675 (32.6%) 0.7 (0.6 to 0.9) <0.01
Operative Diagnosis
Inflammatory arthritis 94/251 (37.5%) 71/205 (34.6%)
AVN 257/687 (37.4%) 1.0 (0.7 to 1.4) 0.99 176/519 (33.9%) 1.0 (0.7 to 1.4) 0.86
Osteoarthritis 3355/7825 (42.9%) 1.3 (1.0 to 1.6) 0.10 2030/5218 (38.9%) 1.2 (0.9 to 1.6) 0.23
Other 117/391 (29.9%) 0.7 (0.5 to 1.0) 0.05 97/301 (32.2%) 0.9 (0.6 to 1.3) 0.59
ASA, American Society of Anesthesiologists; AVN, avascular necrosis of bone; BMI, body mass index; CI, confidence interval; THA, total hip arthroplasty.
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OR of association of diagnosis with moderate-severe
pain at five years and the level of significance showed
minimal change.
Subgroup analyses for patients <65 and those 65 years
and older showed that ORs noted in the main analyses
changed little: OA and AVN patients younger than 65 years
had lower odds of moderate-severe ADL limitation at two
years (0.4 (95% CI 0.2 to 0.9), P = 0.03), and 0.5 (0.2 to 1.0),
P = 0.06) just as those 65 years and older did (0.4 (95% CI
0.2 to 0.9), P = 0.03 and 0.4 (0.2 to 0.8), P = 0.008).
Exploratory univariate and multivariable-adjusted
analyses of limitation in seven activities
In univariate analyses, we found that compared to those
with RA/inflammatory arthritis, patients with OA hadsignificantly lower odds of moderate-severe limitations
in walking, climbing stairs, putting on socks/shoes,
picking up objects and rising from a chair at two years
post-primary THA (Table 5). At five years, results were
similar except that differences were not significant for
walking and rising from a chair. Similarly, compared to
those with RA/inflammatory arthritis, patients with
AVN were significantly less likely to have limitations in
climbing stairs, putting on socks/shoes, picking up ob-
jects and rising from a chair at two years (Table 6); re-
sults were similar at five years (Table 6).
In multivariable-adjusted analyses, patients with OA
had significantly lower odds of limitation in rising from
a chair at two years (Table 6). Patients with AVN had
significantly lower odds of limitation in putting on
shoes/socks or rising from a chair at two years (Table 6).
Table 3 Univariate association of diagnosis with ADL limitation and pain at two and five years after primary THA
Diagnosis
RA/ inflammatory arthritis OA AVN Other
Overall moderate-severe ADL limitation
Two-year follow-up 67/140 (47.9%) 1384/4714 (29.4%) 115/389 (29.6%) 83/192 (43.2%)
P-value compared to RA group <0.01 <0.01 0.43
Five-year follow-up 45/97 (46.4%) 911/2648 (34.4%) 77/246 (31.3%) 62/139 (44.6%)
P-value compared to RA group 0.01 0.02 0.79
Moderate-severe hip pain
Two-year follow-up 7/142 (4.9%) 355/4676 (7.6%) 47/378 (12.4%) 26/194 (13.4%)
P-value compared to RA group 0.02 0.24 0.01
Five-year follow-up 7/93 (7.5%) 270/2651 (10.2%) 37/244 (15.2%) 25/142 (17.6%)
P-value compared to RA group 0.07 0.41 0.03
Reference category is rheumatoid arthritis/inflammatory arthritis and P-values were obtained from univariate logistic regression models. Numbers in bold
represents significant p-value <0.05. ADL, activities of daily living; AVN, avascular necrosis of bone; OA, osteoarthritis; RA, rheumatoid arthritis; THA, total
hip arthroplasty.
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OA had significantly lower odds of limitation in
climbing stairs at five years.Discussion
In this prospective study of a large cohort of patients
with primary THA, we found that after adjusting for im-
portant predictors, patients with OA had significantly
better functional outcomes compared to those with RA/
inflammatory arthritis at two-year follow-up. Results
were notable for overall ADL limitation and key ADLs.
Pain outcomes were not significantly different for OA
versus RA. We also found that patients with AVN expe-
rienced better ADL outcome at two years compared to
RA patients. In contrast, patients with AVN reported
worse pain outcomes at five years compared to those
with RA. Several findings in our study are of interest
and merit further discussion.Table 4 Multivariable-adjusted association of diagnosis with
primary THA
OA
ORa (95% CI) P-value
Moderate-severe overall ADL limitationb
Two-years 0.5 (0.3,0.8) 0.01
Five-years 0.7 (0.4 to 1.4) 0.36
Moderate-severe hip painc
Two-years 1.6 (0.6 to 4.5) 0.40
Five-years 2.1 (0.7 to 6.5) 0.22
aReference category is rheumatoid arthritis/inflammatory arthritis; badjusted for 16
comorbidity score, ASA class, distance from the medical center, cement fixation, pre
10 additional covariates/confounders: age, gender, BMI, Deyo-Charlson comorbidity
preoperative pain, anxiety and depression. Numbers in bold represents significan
Anesthesiologists; AVN, avascular necrosis of bone; BMI, body mass index; CI, confid
THA, total hip arthroplasty.One of the main findings of our study was that patients
with OA had significantly better functional outcomes
compared to those with RA at the two-year follow-up, as
indicated by lower odds of overall moderate-severe ADL
limitation. These findings were confirmed for patients
younger and older than 65 years. To our knowledge, this
is the first study to have analyzed the association of diag-
nosis with functional outcomes adjusted for known corre-
lates of outcome in a large sample of patients at both the
two- and five-year follow-up after primary THA. On the
other hand, we found no significant differences in risk
of moderate-severe pain between OA and RA in
multivariable-adjusted models. The greater ADL limita-
tion noted in RA patients compared to OA patients may
be due to the systemic inflammatory processes in RA ver-
sus OA [28], a higher risk of postoperative dislocation
after primary THA in RA versus OA patients [29], and/or
a more polyarticular disease in RA compared to OA. As
stated previously, ‘A single THR (total hip replacement)ADL limitation and pain at two and five years after
AVN Other
ORa (95% CI) P-value ORa (95% CI) P-value
0.4 (0.2 to 0.8) 0.01 1.0 (0.5 to 1.9) 0.91
0.9 (0.4 to 1.8) 0.78 2.1 (0.9 to 4.8) 0.07
2.8 (0.9 to 8.5) 0.06 2.2 (0.6 to 7.3) 0.22
4.1 (1.2 to 14.1) 0.02 4.2 (1.1 to 16.0) 0.04
additional covariates/confounders: age, gender, BMI, Deyo-Charlson
operative limitation in seven activities, anxiety and depression; cadjusted for
score, ASA class, distance from the medical center, cement fixation,
t p-value <0.05. ADL, activities of daily living; ASA, American Society of
ence interval; OA, osteoarthritis; OR, odds ratio; RA, rheumatoid arthritis;
Table 5 Univariate association of diagnosis with each ADL limitation at two and five years after primary THA
Two years Five years
n/N (%) ORa 95% CI P-value n/N (%) ORa 95% CI P-value
Limitations in walking
RAa 50/141 (35.5%) 1.0 (ref) 38/97 (39.2%) 1.0 (ref)
Osteoarthritis 1298/4815 (27%) 0.7 (0.5 to 1.0) 0.04 927/2723 (34%) 0.8 (0.5 to 1.2) 0.32
AVN 113/397 (28.5%) 0.7 (0.5 to 1.1) 0.15 74/250 (29.6%) 0.7 (0.4 to 1.1) 0.10
Other 70/201 (34.8%) 1.0 (0.6 to 1.6) 0.91 51/145 (35.2%) 0.8 (0.5 to 1.5) 0.55
Limitations in climbing stairs
RA 53/144 (36.8%) 1.0 (ref) 38/98 (38.8%) 1.0 (ref)
Osteoarthritis 818/4873 (16.8%) 0.3 (0.2 to 0.5) <0.01 562/2739 (20.5%) 0.4 (0.3 to 0.6) <0.01
AVN 77/397 (19.4%) 0.4 (0.3 to 0.6) <0.01 48/250 (19.2%) 0.4 (0.2 to 0.6) <0.01
Other 55/202 (27.2%) 0.6 (0.4 to 1.0) 0.07 43/145 (29.7%) 0.7 (0.4 to 1.2) 0.15
Limitations in putting on socks/shoes
RA 57/143 (39.9%) 1.0 (ref) 37/97 (38.1%) 1.0 (ref)
Osteoarthritis 1178/4867 (24.2%) 0.5 (0.3 to 0.7) <0.01 725/2733 (26.5%) 0.6 (0.4 to 0.9) 0.02
AVN 85/400 (21.3%) 0.4 (0.3 to 0.6) <0.01 68/253 (26.9%) 0.6 (0.4 to 1.0) 0.05
Other 74/201 (36.8%) 0.9 (0.6 to 1.4) 0.59 54/144 (37.5%) 1.0 (0.6 to 1.7) 0.92
Limitations in picking up objects
RA 55/145 (37.9%) 1.0 (ref) 40/98 (40.8%) 1.0 (ref)
Osteoarthritis 1153/4873 (23.7%) 0.5 (0.4 to 0.7) <0.01 730/2735 (26.7%) 0.5 (0.3 to 0.8) <0.01
AVN 92/399 (23.1%) 0.5 (0.3 to 0.7) <0.01 63/252 (25%) 0.5 (0.3 to 0.8) <0.01
Other 68/203 (33.5%) 0.8 (0.5 to 1.3) 0.41 50/146 (34.2%) 0.8 (0.4 to 1.3) 0.32
Limitations in getting in/out of car
RA 29/144 (20.1%) 1.0 (ref) 21/98 (21.4%) 1.0 (ref)
Osteoarthritis 703/4864 (14.5%) 0.7 (0.4 to 1.0) 0.06 488/2745 (17.8%) 0.8 (0.5 to 1.3) 0.39
AVN 63/401 (15.7%) 0.7 (0.4 to 1.2) 0.24 40/251 (15.9%) 0.7 (0.4 to 1.3) 0.26
Other 48/202 (23.8%) 1.2 (0.7 to 2.1) 0.43 36/146 (24.7%) 1.2 (0.6 to 2.3) 0.58
Limitations in rising from chair
RA 25/144 (17.4%) 1.0 (ref) 14/98 (14.3%) 1.0 (ref)
Osteoarthritis 353/4852 (7.3%) 0.4 (0.2 to 0.6) <0.01 272/2727 (10%) 0.7 (0.4 to 1.2) 0.17
AVN 39/401 (9.7%) 0.5 (0.3 to 0.9) 0.02 30/252 (11.9%) 0.8 (0.4 to 1.6) 0.55
Other 24/201 (11.9%) 0.6 (0.4 to 1.2) 0.16 18/143 (12.6%) 0.9 (0.4 to 1.8) 0.70
Limitations in sitting
RA 1/143 (0.7%) 1.0 (ref) 1/97 (1%) 1.0 (ref)
Osteoarthritis 44/4850 (0.9%) 1.3 (0.2 to 9.5) 0.8 26/2724 (1%) 0.9 (0.1 to 6.9) 0.94
AVN 9/396 (2.3%) 3.3 (0.4 to 26.3) 0.3 7/251 (2.8%) 2.8 (0.3 to 22.7) 0.35
Other 2/200 (1.0%) 1.4 (0.1 to 16.0) 0.8 3/144 (2.1%) 2.0 (0.2 to 20.0) 0.54
aReference category is rheumatoid arthritis/inflammatory arthritis. --, not applicable, since these ADLs did not have a response for mild limitation category.
Numbers in bold represents significant p-value <0.05, ADL, activities of daily living; AVN, avascular necrosis of bone; CI, confidence interval; OR, odds ratio;
RA, rheumatoid arthritis; THA, total hip arthroplasty.
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but only one of a number of joint problems for most RA
patients’ [9]. It is important to note that in exploratory
analyses, several associations for key ADLs that were sig-
nificant in univariate models were no longer significant in
multivariable-adjusted models, indicating that theseassociations were not independent of the covariates
adjusted in the multivariable analyses. However, results
were significant for rising from a chair and climbing stairs
in multivariable-adjusted models.
Previous studies that have examined functional out-
comes in THA patients have reported contradictory
Table 6 Multivariable-adjusted association of diagnosis with each ADL limitation at two and five years after primary
THA
Two years Five years
ORa 95% CI P-value ORa 95% CI P-value
Limitations in walkingb
Osteoarthritis 0.7 (0.4,1.2) 0.21 0.8 (0.4,1.5) 0.43
AVN 0.8 (0.4,1.7) 0.63 0.8 (0.4,1.8) 0.62
Other 1.3 (0.6,2.7) 0.55 1.2 (0.5,3.1) 0.67
Limitations in climbing stairsb
Osteoarthritis 0.6 (0.3,1.0) 0.07 0.5 (0.3,0.9) 0.03
AVN 0.5 (0.3,1.1) 0.07 0.5 (0.2,1.0) 0.049
Other 1.0 (0.5,2.1) 0.95 0.9 (0.4,2.2) 0.80
Limitations in putting on socks/shoesb
Osteoarthritis 0.7 (0.4,1.1) 0.12 0.7 (0.4,1.3) 0.27
AVN 0.5 (0.3,0.9) 0.03 0.9 (0.4,1.8) 0.72
Other 1.6 (0.8,3.2) 0.16 2.0 (1.0,4.4) 0.07
Limitations in picking up objectsb
Osteoarthritis 0.7 (0.4,1.1) 0.10 0.6 (0.3,1.1) 0.09
AVN 0.6 (0.3,1.1) 0.08 0.8 (0.4,1.6) 0.50
Other 1.1 (0.6,2.3) 0.73 1.5 (0.7,3.3) 0.30
Limitations in getting in/out of carb
Osteoarthritis 1.0 (0.5,2.0) 0.98 0.8 (0.4,1.6) 0.53
AVN 0.9 (0.4,2.0) 0.78 0.9 (0.4,2.1) 0.84
Other 1.1 (0.4,2.9) 0.80 1.5 (0.6,3.7) 0.36
Limitations in rising from chairb
Osteoarthritis 0.4 (0.2,0.9) 0.03 1.0 (0.4,2.5) 0.99
AVN 0.4 (0.2,0.9) 0.04 1.3 (0.4,3.8) 0.66





aReference category is rheumatoid arthritis/inflammatory arthritis; bAdjusted for 16 additional covariates/confounders: age, gender, BMI, Deyo-Charlson
comorbidity score, ASA class, distance from the medical center, cement fixation, preoperative limitation in seven activities, anxiety and depression; N/A, not
applicable, since the model did not run for sitting, due to too few cases. ADL, activities of daily living; ASA, American Society of Anesthesiologists; AVN, avascular
necrosis of bone; BMI, body mass index; CI, confidence interval; OR, odds ratio; RA, rheumatoid arthritis; THA, total hip arthroplasty.
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(walking scores) at two years post-THA did not differ by
the underlying diagnosis [8]. On the other hand, some
studies have reported worse outcomes in patients with
RA compared to OA. In their study of 97 patients,
Borstlap et al. reported that patients with OA experi-
enced better functional outcomes one year after THA
compared to those with RA [9]. A study of 106 RA pa-
tients by Creighton et al. suggested that RA was associ-
ated with less optimal functional improvement at 10
years as compared to other diagnoses (OA, and so on)
in their other studies [11]. Kirwan et al. studied 293patients who underwent total hip or total knee replace-
ment at 2.5 years and found greater improvements in
pain and function in OA compared to RA [10]. Hawker
et al. examined the predictors of successful joint
arthroplasty outcome in a cohort of 233 patients with
either hip or knee joint replacement and found that
RA was associated with 0.33 odds of good outcome
compared to OA, based on WOMAC total score
improvements, a pain and function composite [30].
Two of the four positive studies combined knee and
hip arthroplasty patients, and studies show that out-
comes from these two procedures differ [31], as do the
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pretation of these studies difficult for THA populations.
Previous studies had small sample sizes, heteroge-
neous populations, unadjusted analyses, historical con-
trols and contradictory findings. Our findings from a
multivariable-adjusted analysis from a large total joint
registry provide clarity and add to the current know-
ledge. Our findings suggest that functional outcomes
were better in OA versus RA and that there were no
significant differences in pain outcomes two years and
five years after THA.
Another important study finding was the lack of differ-
ence in pain outcomes in RA versus OA patients after
THA. This is reassuring given that the most common
symptom leading to THA is severe, refractory hip joint
pain. This implies that patients with RA can be
reassured that their pain outcomes will be similar to the
majority of patients with OA undergoing THA.
Another interesting finding from our study is that pa-
tients with AVN were less likely to have moderate-
severe ADL limitations and more likely to report
moderate-severe pain compared to patients with RA. To
our knowledge, this is a new finding and adds to the lit-
erature. A recent systematic review of outcomes of THA
in patients with AVN found that most studies had a low
evidence level of III and IV and provided data only re-
lated to revision rates [34], indicating a lack of studies of
PROs in this patient population. Our finding of worse
pain outcomes in AVN patients compared to RA pa-
tients might indicate the difference in pathophysiology
of the two conditions (AVN versus RA) and polyarticular
and bilateral involvement with RA [9] compared to
AVN. In addition, documented high rates of early com-
plications and reoperations in AVN patients (17% and 11%,
respectively, at an average follow-up of 20 months) [35]
may also explain better ADL outcomes in AVN versus RA.
The practical implications of our study are several-fold.
First our study highlights the importance of studying both
pain and functional outcomes in arthroplasty patients, as
discussed previously [36]. Although these domains are
somewhat interrelated, they can be discordant due to dif-
ferent slopes of recovery post-arthroplasty; for example, at
three months post-THA, patients are likely to report sig-
nificant improvement in pain, but function may be the
same as it was preoperatively due to continuing recovery
and rehabilitation. Similarly, other lower extremity joint
involvement and back problems impact pain and function
differently, that is, the impact on function may be tremen-
dous, but there may be no impact on index hip pain. Our
study further demonstrates that the underlying diagnosis
impacts pain and function after primary THA differently.
This new information can help surgeons inform their pa-
tients preoperatively during the informed consent process
with regard to expected outcomes after primary THA,based on their underlying diagnosis. Given the longevity
of the implant and the elective nature of the surgery, a
better insight into why certain diagnoses are associated
with worse outcome can help to improve these outcomes
even further, if modifiable intermediate factors can be
identified. This will also lead to even more informed pa-
tients and reduction of unsatisfactory outcome after pri-
mary THA, a highly successful surgery.
Our study has several limitations and strengths. Survey
non-response may have introduced some bias, and the
direction of this bias is unclear. Our response rates are
similar to the average 60% response rate reported for
large surveys of this size [37]; however, the five-year esti-
mates should be interpreted with caution. Due to a co-
hort study design, residual confounding is possible,
despite inclusion of multiple clinical and demographic
variables. There may be some misclassification of opera-
tive diagnosis due to similarity of gross findings at sur-
gery between RA and AVN and because classification
criteria are not used in clinical orthopedic practice for
RA and are not available for AVN. However, the surgeon
incorporates history, examination and medication use in
making the diagnosis that should provide good accuracy.
Misclassification bias may have biased our results to-
wards null. Generalizability is always a challenge, but the
similarity of our cohort to other hip arthroplasty cohorts
indicates that results may be generalizable to other set-
tings [6,7,38]. Study strengths include a follow-up at two
time-points, large sample size to allow adequate power,
prospective data collection by dedicated Total Joint
Registry staff and multivariable-adjusted analyses that
adjusted for other factors known/likely to be associated
with the outcomes.
Conclusions
Our study is among the first well-powered studies ad-
justed for important covariates and confounders that
showed that the underlying diagnosis for primary THA
is a significant predictor of functional outcomes and
pain up to five years post-THA. We found that com-
pared to RA, OA was associated with better overall
functional outcome after primary THA. Compared to
RA, AVN was associated with better overall functional
and worse pain outcomes after primary THA. Future
studies need to investigate the underlying pathophysi-
ology and reasons for these significant findings, which
can help us understand better the true mechanism of
pain and functional outcomes after primary THA.
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